Unfortunately, patient survival for grade IV gliomas is between 16–22 months with current standard-of-care (SOC) treatments [1], which includes surgical tumor resection, and follow up therapies including radiation, chemotherapy (temozolomide or TMZ (the most commonly used)) and possible treatment with bevacizumab (an antibody therapy targeting the vascular endothelial growth factor or VEGF). Here, VEGFA is linked to central nervous system cancer.